Corcept Therapeutics (CORT) Revenue (2012 - 2026)
Corcept Therapeutics (CORT) posted Revenue of $256.1 million for Q2 2026, up 55.33% sequentially from $164.9 million in Q1 2026, and up 31.74% YoY from $194.4 million in Q2 2025.
Corcept Therapeutics (CORT) Revenue (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported Revenue for 15 years, with the latest figure at $256.1 million in Q2 2026.
- Quarterly Revenue rose 31.74% year-over-year to $256.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $830.8 million (up 16.02% YoY) and the FY2025 annual result came in at $761.4 million, up 12.79% from the prior year.
- Revenue climbed to $256.1 million in Q2 2026 per CORT's latest filing, from $164.9 million in the prior quarter.
- Over five years, Revenue peaked at $256.1 million in Q2 2026 and troughed at $93.7 million in Q1 2022.
- A 5-year average of $152.3 million and a median of $152.0 million in 2024 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2024: Revenue increased 4.28% in 2022, then soared 47.69% in 2024.
- Over 5 years, Revenue stood at $103.1 million in 2022, then jumped by 31.39% to $135.4 million in 2023, then soared by 34.33% to $181.9 million in 2024, then climbed by 11.12% to $202.1 million in 2025, then gained by 26.73% to $256.1 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $256.1 million, $164.9 million, and $202.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 256.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 256.15 Mn |
| Mar 31, 2026 | 164.90 Mn |
| Dec 31, 2025 | 202.13 Mn |
| Sep 30, 2025 | 207.64 Mn |
| Jun 30, 2025 | 194.43 Mn |
| Mar 31, 2025 | 157.21 Mn |
| Dec 31, 2024 | 181.89 Mn |
| Sep 30, 2024 | 182.55 Mn |
| Jun 30, 2024 | 163.80 Mn |
| Mar 31, 2024 | 146.81 Mn |
| Dec 31, 2023 | 135.41 Mn |
| Sep 30, 2023 | 123.60 Mn |
| Jun 30, 2023 | 117.72 Mn |
| Mar 31, 2023 | 105.65 Mn |
| Dec 31, 2022 | 103.06 Mn |
| Sep 30, 2022 | 101.73 Mn |
| Jun 30, 2022 | 103.39 Mn |
| Mar 31, 2022 | 93.69 Mn |
| Dec 31, 2021 | 98.82 Mn |
| Sep 30, 2021 | 96.13 Mn |